Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6109049 | 1.00 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL6095669 | 0.96 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL6095662 | 0.96 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL6291361 | 0.96 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL6096924 | 0.93 | SLC6A4 (0.36) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL6095814 | 0.93 | SLC6A4 (0.36) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL6093000 | 0.92 | SLC6A4 (0.36) | SLC6A2SLC6A4SLC6A3HTR2CHTR2B | |
| SCHEMBL6094320 | 0.92 | SLC6A4 (0.36) | SLC6A2SLC6A4SLC6A3HTR2CHTR2B | |
| SCHEMBL6094520 | 0.91 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL6096695 | 0.91 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605941-A1 | SUBSTITUTED PIPERIDINES AS NOVEL MDM2-p53 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-21 | — | — | EP | claimed |
| US-6916833-B2 | Substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | claimed |
| WO-2004080460-A1 | SUBSTITUTED PIPERIDINES AS NOVEL MDM2-p53 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | claimed |
| US-20040180929-A1 | Nitrogen compounds such as 4-Benzyloxy-4-(4-chlorophenyl)-3-(3,4-difluorobenzyloxy)-piperidine, administered as oncoprotein or ubiquitin-conjugating enzyme antagonists for prophylaxis of cancer; anticarcinogenic agents | KIM KYUNGJIN (US) | 2004-09-16 | — | — | US | claimed |
| US-7060713-B2 | Substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20050171157-A1 | 3-alkyl- or alkenyloxy-4-phenyl-4-phenylalkoxypiperidines that may be N-substituted, e.g., cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-butyloxy-piperidine; treating breast or colon cancer | KIM KYUNGJIN (US) | 2005-08-04 | — | — | US | disclosed |
| US-6916833-B2 | Substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20040180929-A1 | Nitrogen compounds such as 4-Benzyloxy-4-(4-chlorophenyl)-3-(3,4-difluorobenzyloxy)-piperidine, administered as oncoprotein or ubiquitin-conjugating enzyme antagonists for prophylaxis of cancer; anticarcinogenic agents | KIM KYUNGJIN (US) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171157-A1 | 3-alkyl- or alkenyloxy-4-phenyl-4-phenylalkoxypiperidines that may be N-substituted, e.g., cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-butyloxy-piperidine; treating breast or colon cancer | KRAS, TMEM205, ABCB11 | SLC6A2 515/4885SLC6A4 425/4885SLC6A3 1729/4885 |
| US-20040180929-A1 | Nitrogen compounds such as 4-Benzyloxy-4-(4-chlorophenyl)-3-(3,4-difluorobenzyloxy)-piperidine, administered as oncoprotein or ubiquitin-conjugating enzyme antagonists for prophylaxis of cancer; anticarcinogenic agents | PSMB1, UBQLN1, UBE2N | SLC6A2 3796/4885SLC6A4 4038/4885SLC6A3 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.